Monitoring levels of MMP-2 and MMP-9 in patients could serve as a biomarker to assess the aggressiveness of the tumor, predict prognosis, or evaluate the effectiveness of gelatinase inhibitors as part of the treatment regimen [44]. The gene discussed is MMP9; the disease is neoplasm.